Topic
Topic
Dermatology Times spotlights three atopic dermatitis storylines from EADV 2026 in Europe: the biologic tilrekimig, RAC2 pathway inhibition, and fresh Level Up study data shaping the next wave of biol…
Tilrekimig, a triple-targeting biologic, eased established eczema in an early-phase trial, Medscape reports — a directional signa…
Triple-targeting biologic tilrekimig eased established eczema in an early trial, Medscape reports. Effect sizes, cohort and safet…
Pfizer's tilrekimig produced Phase II skin clearance in atopic dermatitis and is positioned for a direct head-to-head against dup…
Pfizer's investigational IL-17 inhibitor tilrekimig produced a significant skin clearance signal in a Phase 2 atopic dermatitis t…
Tilrekimig, a first-in-class trispecific antibody targeting IL-4, IL-13 and TSLP, delivered EASI-75 rates up to 62.5% at Week 16…
Pfizer has disclosed Phase 2 atopic dermatitis results for tilrekimig, its mid-stage candidate; detailed efficacy and safety data…
Pfizer reports its investigational tilrekimig achieved significant skin clearance in a Phase 2 atopic dermatitis study, advancing…
Pfizer advances tilrekimig into pivotal atopic dermatitis and asthma trials on the strength of Phase II AD data, deepening its ty…
